| |||||
| |||||
|
Tuesday, September 19, 2023
Planet Fitness cut to Neutral at 3 Sell Siders
President and CEO Sells 27,917 Shares of Pyxis Oncology
Lara Sullivan is a seasoned executive in the biopharmaceutical industry. She has a proven track record of leading and growing companies in the oncology sector. As the President and CEO of Pyxis Oncology Inc, she has been instrumental in the company's growth and development.
Pyxis Oncology Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the lives of patients with cancer. The company's unique approach to cancer treatment involves leveraging the body's immune system to fight cancer cells. Pyxis Oncology Inc is committed to bringing innovative treatments to patients who need them the most.
Over the past year, the insider has sold a total of 27,917 shares and purchased 0 shares. This trend of selling shares is not uncommon among insiders, especially when the company's stock is performing well. However, it's important to note that insider selling does not necessarily indicate a negative outlook for the company.
https://finance.yahoo.com/news/insider-sell-president-ceo-lara-210324518.html
Symetryx exits stake in NeuBase
NeuBase Therapeutics (NASDAQ:NBSE) falls 14% after disclosing that Symetryx has sold its entire position in the biopharmaceutical company.
https://seekingalpha.com/news/4013366-symetryx-exits-stake-in-neubase-therapeutics-shares-fall
Creative Medical OKd to Initiate Phase 1/2 Trial for Treatment of Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company to proceed with a Phase 1/2 clinical trial of StemSpine® using AlloStem™ ("CELZ-201-DDT").
https://finance.yahoo.com/news/creative-medical-technology-holdings-receives-120000984.html
Bandera Partners LLC Boosts Stake in The Joint Corp
On September 18, 2023, Bandera Partners LLC (Trades, Portfolio) added 77,436 shares of The Joint Corp to its portfolio at a trade price of $9.25 per share. This transaction increased Bandera Partners LLC (Trades, Portfolio)'s total holdings in The Joint Corp to 3,696,434 shares, representing 14.47% of its portfolio and 25.08% of The Joint Corp's outstanding shares. The transaction had a 0.3% impact on Bandera Partners LLC (Trades, Portfolio)'s portfolio.
Profile of Bandera Partners LLC (Trades, Portfolio)
Bandera Partners LLC (Trades, Portfolio) is an investment firm located at 50 Broad Street, Suite 1820, New York, NY 10004. The firm's portfolio consists of 18 stocks, with a total equity of $236 million. Its top holdings include Alphabet Inc (NASDAQ:GOOG), Alphabet Inc (NASDAQ:GOOGL), The Joint Corp (NASDAQ:JYNT), Star Group LP (NYSE:SGU), and Burford Capital Ltd (NYSE:BUR). The firm's investments are primarily concentrated in the healthcare and energy sectors.
Overview of The Joint Corp
The Joint Corp, based in the USA, operates and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sale of regional developer rights. The company has two business segments: Corporate Clinics and Franchise Operations. As of September 19, 2023, The Joint Corp has a market capitalization of $151.912 million and a stock price of $9.98. The company's PE percentage is 47.52, indicating that it is currently profitable.
https://finance.yahoo.com/news/bandera-partners-llc-boosts-stake-190509428.html
Eli Lilly sues over US sales of bogus Mounjaro for weight loss
Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, the active ingredient in its diabetes drug Mounjaro which is expected to be approved for weight loss later this year.
In four separate lawsuits filed in Florida and Texas federal courts, Eli Lilly is seeking orders barring Better Life Pharmacy, ReviveRX, Rx Compound Store and Wells Pharmacy Network from selling tirzepatide, and requesting unspecified damages.
The Indianapolis-based drugmaker is accusing the four compounding pharmacies, which make customized drug preparations for customers, of violating federal and state consumer protection and competition laws by selling unregulated versions of Mounjaro.
Lilly is the only company with U.S. Food and Drug Administration approval to sell tirzepatide drugs.
The drugmaker is seeking similar injunctive orders and damages against six medical spas and wellness centers from federal courts in Arizona, Florida, Georgia, Minnesota, South Carolina and Utah, accusing them of infringing its trademark by advertising compounded tirzepatide as Mounjaro.
"Defendants use Lilly’s trademark to attract customers and generate revenues and profits, including by passing off as 'Mounjaro' their own unapproved compounded drugs purporting to contain tirzepatide, and doing so for a use for which Mounjaro is not approved, namely weight loss," Eli Lilly said in the lawsuits.
The suits come just over two months after rival Novo Nordisk, which markets the popular obesity treatment Wegovy, sued several medical spas and three compounding pharmacies for selling products claiming to contain semaglutide, the main ingredient in Wegovy and the related diabetes drugs Ozempic and Rybelsus.
Lilly in a statement said, “products claiming to contain tirzepatide that are made and/or distributed by compounding pharmacies or distributed by counterfeit sources have not been reviewed by the U.S. FDA or global regulatory agencies for safety, quality, or efficacy.”
https://finance.yahoo.com/news/eli-lilly-sues-over-us-190641447.html
Subscribe to:
Posts (Atom)